Intervertebral disc degeneration
Drug research and approvals for intervertebral disc degeneration: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 52 studies of intervertebral disc degeneration are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 52
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Association of Subcutaneous Fat Index, Paraspinal Muscle Characteristics, and Facet Morphology With Lumbar Facet Joint…NCT07860697 · Not reported · Marmara University · starts Sep 1, 2026
- Effect of Irrigation Pressure on Postoperative Complications and Surgical Field Clarity in Unilateral Biportal…NCT07837427 · Not applicable · Fan Zhang · starts Feb 5, 2026
- PMCF Study Fortilink-TC TiNCT07834931 · Not reported · BAAT Medical Products B.V. · starts Jan 1, 2026
- PMCF Study Fortilink-TS TiNCT07834736 · Not reported · BAAT Medical Products B.V. · starts Jan 1, 2026
- PMCF Study Fortilink-SCNCT07834749 · Not reported · BAAT Medical Products B.V. · starts Jan 1, 2026
- More Realistic Spine Patients: Assessing the Effect of Dialogue Support Tool.NCT07788872 · Not applicable · University Hospital, Akershus · starts Sep 1, 2026
- The Effect of NSAID on Serum PeriostinNCT07662668 · Not reported · Keimyung University Dongsan Medical Center · starts Jun 22, 2026
- PMCF Study on the Effectiveness and Safety of METROSAN Spinal Systems and BONEGRAFT Filling MaterialsNCT07615491 · Not reported · Metrosan End. ve Elk. Mek. Cihazlar ve Tibbi Malz. San. Tic. Ltd. Co. · starts Apr 27, 2026
- Patient Reported Outcome Measurements Registration in Spinal Pathologies and NeuromodulationNCT07552519 · Not reported · Jessa Hospital · starts Apr 1, 2026
Phase 3 4
- Rexlemestrocel-l
- BuprenorphineMu opioid receptor agonist
- PregabalinVoltage-gated calcium channel modulator
- GabapentinVoltage-gated calcium channel modulator
Phase 2 3
- Radotermin
- Tranexamic acidPlasminogen inhibitor
- Water
Phase 1 or earlier 5
- Rebonuputemcel
- AcetaminophenCyclooxygenase inhibitor
- MethadoneMu opioid receptor agonist
- OxycodoneMu opioid receptor agonist
- LorecivivintDual specificity tyrosine-phosphorylation-regulated kinase 1A inhibitor
How its trials ended
441 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 107 whose ending is known, 21% met their primary endpoint, 1% missed it and 78% stopped early.
- Completed, result not reported15836%
- Ongoing11326%
- Status unknown6314%
- Stopped: other or unclear4610%
- Met its primary endpoint235%
- Stopped: enrollment or feasibility205%
- Stopped: sponsor or business decision143%
- Stopped: lack of efficacy2<1%
- Missed its primary endpoint1<1%
- Stopped: funding1<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA